The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Open accessAbstract
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our patient’s tumor harbored mutations in TERT, FUBP1, and CIC, which are common alterations in oligodendroglioma, but not clinically relevant [46,47].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“IDH WT astrocytomas are, for the most part, highly aggressive, having a median survival of 18 mo”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“Second, predicted risks are consistent with the published expected overall survivals associated with molecular subtypes (37).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“and these have the lowest overall predicted risks consistent with overall survivals of 10+ y (37, 39).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“IDH mutant astrocytomas are another subtype with considerably better overall survival ranging from 3 to 8 y”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“In recent years, two landmark genomic studies carried out in human glioma and acute myeloid leukaemia (AML) found mutations in IDH1/2 and it is now appreciated that these enzymes (which drive elevated production of D-2-HG) are the most frequently mutated metabolic genes in human cancer112-114.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Parker BC, 2013, J Clin Invest, 123, 855
Cited by
Sorted by citations
Items 701–800 of 1,002
CoxKAN: Kolmogorov-Arnold networks for interpretable, high-performance survival analysis
Knottenbelt, W. J., McGough, W., Wray, R., Zhang, W. Z., Liu, J., Machado, I. P., Gao, Z., & Crispin‐Ortuzar, M. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf413 · Cited by 61
Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 46
Characteristics of gliomas in patients with somatic IDH mosaicism
Bonnet, C., Thomas, L., Psimaras, D., Bielle, F., Vauléon, É., Loiseau, H., Cartalat‐Carel, S., Meyronet, D., Dehais, C., Honnorat, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0302-y · Cited by 43
Surgical approaches for the gliomas
Watts, C., & Sanai, N. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00004-9 · Cited by 46
Safaee, M., Englot, D. J., Han, S. J., Lawton, M. T., & Berger, M. S. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2154-5 · Cited by 43
Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
Lubanska, D., & Porter, L. A. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0180-1 · Cited by 46
Does early resection of presumed low-grade glioma improve survival? A clinical perspective
Wijnenga, M. M. J., Mattni, T., French, P. J., Rutten, G.-J. M., Leenstra, S., Kloet, F., TAPHOORN, M. J. B., van den Bent, M. J., Dirven, C. M. F., van Veelen, M. C., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2418-8 · Cited by 44
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas
Hayes, J. L., Yu, Y., Jalbert, L. E., Mazor, T., Jones, L. E., Wood, M. D., Walsh, K. M., Bengtsson, H. L., Hong, C., Oberndorfer, S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox205 · Cited by 43
Ius, T., Ciani, Y., Ruaro, M. E., Isola, M., Sorrentino, M., Bulfoni, M., Candotti, V., Correcig, C., Bourkoula, E., Manini, I., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox234 · Cited by 43
New Directions in the Treatment of Glioblastoma
Reitman, Z. J., Winkler, F., & Elia, A. E. H. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1623534 · Cited by 45
Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics—Relevance to Glioma
Chiang, G. C.-Y., Kovanlıkaya, İ., Choi, C., Ramakrishna, R. R., Magge, R., & Shungu, D. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00033 · Cited by 43
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery
Feyissa, A. M., Worrell, G. A., Tatum, W. O., Mahato, D., Brinkmann, B. H., Rosenfeld, S. S., ReFaey, K., Bechtle, P. S., & Quiñones‐Hinojosa, A. (2018) · Neurology · doi:10.1212/wnl.0000000000005216 · Cited by 43
Gowda, P., Patrick, S., Singh, A., Sheikh, T., & Sen, E. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00001-18 · Cited by 43
Role of CX3CR1 signaling in malignant transformation of gliomas
Lee, S., Latha, K., Manyam, G. C., Yang, Y., Rao, A. U. K., & Rao, G. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa075 · Cited by 44
Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma
Zhang, M., Wang, X., Chen, X., Guo, F., & Hong, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00441 · Cited by 43
Importance and Evidence of Extent of Resection in Glioblastoma
Wykes, V., Zisakis, A. K., Irimia, M., Ughratdar, I., Sawlani, V., & Watts, C. (2020) · Journal of Neurological Surgery Part A Central European Neurosurgery · doi:10.1055/s-0040-1701635 · Cited by 45
Wang, J., Zheng, X., Zhang, J., Xue, H., Wang, L., Jing, R., Chen, S., Che, F., Heng, X., Li, G., et al. (2021) · European Radiology · doi:10.1007/s00330-020-07581-3 · Cited by 43
A rapid genotyping panel for detection of primary central nervous system lymphoma
Gupta, M., Burns, E. J., Georgantas, N. Z., Thierauf, J., Nayyar, N., Gordon, A., Jones, S. S., Pisapia, M., Sun, Y., Burns, R. P., et al. (2021) · Blood · doi:10.1182/blood.2020010137 · Cited by 45
Kihira, S., Tsankova, N. M., Bauer, A., Sakai, Y., Mahmoudi, K., Zubizarreta, N. J., Houldsworth, J., Khan, F., Salamon, N., Hormigo, A., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab051 · Cited by 43
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Maggio, I., Lodi, R., & Brandes, A. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00537-3 · Cited by 44
Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
Huang, L. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020246 · Cited by 43
TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy
Noor, H., Briggs, N., McDonald, K. L., Holst, J., & Vittorio, O. (2021) · Cancers · doi:10.3390/cancers13215362 · Cited by 42
WHO Grade Loses Its Prognostic Value in Molecularly Defined Diffuse Lower-Grade Gliomas
Carstam, L., Corell, A., Smits, A., Dénes, A., Barchéus, H., Modin, K., Sjögren, H., Vega, S. F., Bontell, T. O., Carén, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.803975 · Cited by 42
The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer
Pang, Y. K., Chen, X., Ji, T., Cheng, M., Wang, R., Zhang, C., Liu, M., Zhang, J., & Zhong, C. (2023) · Cancers · doi:10.3390/cancers15082228 · Cited by 46
Big data visualization identifies the multidimensional molecular landscape of human gliomas
Bolouri, H., Zhao, L. P., & Holland, E. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601591113 · Cited by 42
The possibility of cancer immune editing in gliomas. A critical review
Arrieta, V. A., Díaz, B. C., Zhao, J., Rabadán, R., Chen, L., & Sonabend, A. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445458 · Cited by 43
Carlo, D. T. D., Duffau, H., Cagnazzo, F., Benedetto, N., Morganti, R., & Perrini, P. (2018) · Neurosurgical Review · doi:10.1007/s10143-018-0996-3 · Cited by 44
Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing
Cantero, D., de Lope, Á. R., de la Presa, R. M., Sepúlveda-Sánchez, J. M., Moreno, J. M. B., Castresana, J. S., D’Haene, N., García, J. F., Salmon, I. J., Mollejo, M., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly048 · Cited by 42
Guo, H., Kang, H., Tong, H., Du, X., Liu, H., Tan, Y., Yang, Y., Wang, S., & Zhang, W. (2018) · European Radiology · doi:10.1007/s00330-018-5738-y · Cited by 42
Characterization of Transcriptome Transition Associates Long Noncoding RNAs with Glioma Progression
Li, X., Jiang, T., Bai, J., Li, J., Wang, T., Xiao, J. Y., Tian, Y., Jin, X., Shao, T., Xu, J., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.10.009 · Cited by 42
Durán, R. C., Wang, C.-Y., Zheng, H., Deneen, B., & Wu, J. Q. (2019) · eNeuro · doi:10.1523/eneuro.0288-18.2019 · Cited by 42
Bier, A., Hong, X., Cazacu, S., Goldstein, H., Rand, D., Xiang, C., Jiang, W., Ben‐Asher, H. W., Attia, M., Brodie, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03088-3 · Cited by 42
Kulinich, D. P., Sheppard, J. P., Nguyen, T. P., Kondajji, A. M., Unterberger, A., Duong, C., Enomoto, A., Patel, K. S., & Yang, I. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-04794-3 · Cited by 42
Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models
Irvin, D., McNeill, R. S., Bash, R., & Miller, C. R. (2016) · Brain Pathology · doi:10.1111/bpa.12348 · Cited by 42
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression
Pirozzi, C. J., Carpenter, A. B., Waitkus, M. S., Wang, C. Y., Zhu, H., Hansen, L. J., Chen, L. H., Greer, P. K., Feng, J., Wang, Y., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0485 · Cited by 42
Goyal, A., Yolcu, Y. U., Goyal, A., Kerezoudis, P., Brown, D. A., Graffeo, C. S., Goncalves, S., Burns, T. C., & Parney, I. F. (2019) · Neurosurgical FOCUS · doi:10.3171/2019.9.focus19660 · Cited by 41
Transcriptomic and connectomic correlates of differential spatial patterning among gliomas
Romero-García, R., Mandal, A. S., Bethlehem, R. A. I., Crespo‐Facorro, B., Hart, M. G., & Suckling, J. (2022) · Brain · doi:10.1093/brain/awac378 · Cited by 42
Mo, Z., Xin, J., Chai, R., Woo, P. Y. M., Chan, D. T. M., & Wang, J. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0418 · Cited by 41
Guo, X., Shi, Y., Liu, D., Li, Y., Chen, W., Wang, Y., Wang, Y., Xing, H., Xia, Y., Li, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1131642 · Cited by 41
Rosberg, R., Smoląg, K. I., Sjölund, J., Johansson, E., Bergelin, C., Wahldén, J., Pantazopoulou, V., Ceberg, C. P., Pietras, K., Blom, A. M., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179854 · Cited by 43
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas
Wu, J., Castro, L. N. G., Battaglia, S., Farran, C. A. E., D’Antonio, J. P., Miller, T. E., Suvà, M. L., & Bernstein, B. (2024) · Nature Cancer · doi:10.1038/s43018-024-00865-3 · Cited by 48
Lee, J. C., Solomon, D. A., & Tihan, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2349-9 · Cited by 45
CDK5 Inhibition Resolves PKA/cAMP-Independent Activation of CREB1 Signaling in Glioma Stem Cells
Mukherjee, S., Tucker‐Burden, C., Kaissi, E., Newsam, A. D., Duggireddy, H., Chau, M. J., Zhang, C., Diwedi, B., Rupji, M., Seby, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.016 · Cited by 41
Jang, B., & Kim, I. A. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.003 · Cited by 41
Grade II and III Oligodendroglioma and Astrocytoma
van den Bent, M. J., & Chang, S. M. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.005 · Cited by 44
Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction
Gondim, D. D., Gener, M., Curless, K. L., Cohen‐Gadol, A., Hattab, E. M., & Liang Cheng, C. (2018) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000702 · Cited by 41
A Multi-Cohort and Multi-Omics Meta-Analysis Framework to Identify Network-Based Gene Signatures
Shafi, A., Nguyen, T., Peyvandipour, A., Nguyen, H., & Drăghici, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00159 · Cited by 43
Tabibkhooei, A., Izadpanahi, M., Arab, A., Zare‐Mirzaie, A., Minaeian, S., Rostami, A., & Mohsenian, A. (2019) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2019.105652 · Cited by 41
Brown, H. M., Alfaro, C. M., Pirro, V., Dey, M., Hattab, E. M., Cohen‐Gadol, A., & Cooks, R. G. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa233 · Cited by 41
Huang, X., Zhang, F., He, D., Ji, X., Gao, J., Liu, W., Wang, Y., Liu, Q., & Xin, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646060 · Cited by 43
Fountain, D. M., Allen, D., Joannides, A. J., Nandi, D., Santarius, T., & Chari, A. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now107 · Cited by 41
Wu, S., Zhang, X., Rui, W., Sheng, Y., Yang, Y., Zhang, Y., Yao, Z., Qiu, T., & Ren, Y. (2022) · European Radiology · doi:10.1007/s00330-021-08444-1 · Cited by 40
Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis
Chanoch-Myers, R., Wider, A., Suvà, M. L., & Tirosh, I. (2022) · Genome Medicine · doi:10.1186/s13073-022-01109-8 · Cited by 40
Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5
Jeon, H.-M., Oh, Y. T., Shin, Y. J., Chang, N., Kim, D., Woo, D., Yeup, Y., Joo, K. M., Jo, H., Yang, H., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100894 · Cited by 41
Cancer metabolism as a central driving force of glioma pathogenesis
Masui, K., Cavenee, W. K., & Mischel, P. S. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0265-5 · Cited by 40
Boudoulas, K. D., Triposkiadis, F. K., Stefanadis, C., & Boudoulas, H. K. (2017) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2017.05.001 · Cited by 41
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics
Vega, J. E. V., & Brat, D. J. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000186 · Cited by 40
Qian, Z., Li, Y., Sun, Z., Fan, X., Xu, K., Wang, K., Li, S., Zhang, Z., Jiang, T., Liu, X., et al. (2018) · Aging · doi:10.18632/aging.101594 · Cited by 43
DNA demethylation is associated with malignant progression of lower-grade gliomas
Nomura, M., Saito, K., Aihara, K., Nagae, G., Yamamoto, S., Tatsuno, K., Ueda, H., Fukuda, S., Umeda, T., Tanaka, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38510-0 · Cited by 40
TERT, a promoter of CNS malignancies
Patel, B., Taiwo, R., Kim, A. H., & Dunn, G. P. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa025 · Cited by 41
IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas
Fujita, Y., Nunez-Rubiano, L., Dono, A., Bellman, A., Shah, M., Rodrı́guez, J. C., Putluri, V., Kamal, A. H. M., Putluri, N., Riascos, R., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04060-1 · Cited by 39
He, J., Zhao, Y., Zhao, E., Wang, X., Dong, Z., Chen, Y., Yang, L., & Cui, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy037 · Cited by 39
Gao, Y., Weenink, B., van den Bent, M. J., Erdem‐Eraslan, L., Kros, J. M., Smitt, P. A. E. S., Hoang‐Xuan, K., Brandes, A. A., Vos, M. J., Dhermain, F. G., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.023 · Cited by 40
Hafazalla, K., Sahgal, A., Jaja, B. N. R., Perry, J., & Das, S. (2018) · Oncotarget · doi:10.18632/oncotarget.25890 · Cited by 40
Caponegro, M. D., Moffitt, R. A., & Tsirka, S. E. (2018) · Oncotarget · doi:10.18632/oncotarget.26273 · Cited by 39
Gulaia, V. S., Kumeiko, V. V., Shved, N. A., Cicinskas, E., Александрович, Р. С., Ruzov, A. S., & Kagansky, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00388 · Cited by 39
Latysheva, A., Emblem, K. E., Brandal, P., Vik-Mo, E. O., Pahnke, J., Røysland, K., Hald, J. K., & Server, A. (2019) · Neuroradiology · doi:10.1007/s00234-019-02173-5 · Cited by 41
The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas
Jones, D., Bandopadhayay, P., & Jabado, N. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031642 · Cited by 41
Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas
Berens, M. E., Sood, A., Barnholtz‐Sloan, J. S., Graf, J. F., Cho, S., Kim, S., Kiefer, J., Byron, S. A., Halperin, R. F., Nasser, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219724 · Cited by 39
Whole slide images reflect DNA methylation patterns of human tumors
Zheng, H., Momeni, A., Cedoz, P.-L., Vogel, H. S., & Gevaert, O. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0120-9 · Cited by 41
Truong, A. H., Sharmanska, V., Limbӓck-Stanic, C., & Grech‐Sollars, M. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa110 · Cited by 39
MYC in Brain Development and Cancer
Zaytseva, O., Kim, N., & Quinn, L. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207742 · Cited by 44
Bumes, E., Wirtz, F.-P., Fellner, C., Grosse, J., Hellwig, D., Oefner, P. J., Häckl, M., Linker, R. A., Proescholdt, M. A., Schmidt, N. O., et al. (2020) · Cancers · doi:10.3390/cancers12113406 · Cited by 39
Su, C., Xu, S., Lin, D., He, H., Chen, Z., Damen, F. C., Ke, C., Lv, X., & Cai, K. (2021) · European Radiology · doi:10.1007/s00330-021-08175-3 · Cited by 39
Wang, Y., Luo, R., Zhang, X., Xiang, H., Yang, B., Feng, J., Deng, M., Ran, P., Sujie, A., Zhang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36005-1 · Cited by 39
RetractedMa, S., Sun, R., Jiang, B., Gao, J., Deng, W., Liu, P., He, R., Cui, J., Ji, M., Yi, W., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00492-16 · Cited by 39
Chen, E., Ling, A. L., Reardon, D. A., & Chiocca, E. A. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad211 · Cited by 38
Pisapia, D. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0493-ra · Cited by 43
Im, J. H., Hong, J. B., Kim, S. H., Choi, J., Chang, J. H., Cho, J., & Suh, C. (2018) · Scientific Reports · doi:10.1038/s41598-017-19014-1 · Cited by 38
Hwang, I., Cao, D., Na, Y., Kim, D.-Y., Zhang, T., Yao, J., Oh, H., HU, J. L., Zheng, H., Yao, Y., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.02.013 · Cited by 38
Molecular Pathogenesis of Low-Grade Glioma
Bready, D., & Placantonakis, D. G. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.011 · Cited by 40
Wang, S., Liu, F., Wang, Y., Fan, W., Zhao, H., Liu, L., Cen, C., Jiang, X., Sun, M., & Han, P. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1930-3 · Cited by 38
Detection of statistically significant network changes in complex biological networks
Mall, R., Cerulo, L., Bensmail, H., Iavarone, A., & Ceccarelli, M. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0412-6 · Cited by 38
Li, J., Wuethrich, A., Dey, S., Lane, R. E., Sina, A. A. I., Wang, J., Wang, Y., Puttick, S. G., Koo, K. M., & Trau, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909306 · Cited by 38
Zheng, S., & Tao, W. (2021) · Cancers · doi:10.3390/cancers13051013 · Cited by 38
Arora, A., Olshen, A. B., Seshan, V., & Shen, R. (2020) · Genome Medicine · doi:10.1186/s13073-020-00804-8 · Cited by 38
Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma
Lv, L., Zhang, Y., Zhao, Y., Wei, Q., Zhao, Y., & Yi, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.704344 · Cited by 38
Heiland, D. H., Staszewski, O., Hirsch, M., Masalha, W., Franco, P., Grauvogel, J., Capper, D., Schrimpf, D., Urbach, H., & Weyerbrock, A. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw007 · Cited by 38
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Viswanath, P., Chaumeil, M. M., & Ronen, S. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00060 · Cited by 38
The Role of Molecular Diagnostics in the Management of Patients with Gliomas
Wirsching, H., & Weller, M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0430-4 · Cited by 39
Environmental and sex-specific molecular signatures of glioma causation
Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab103 · Cited by 39
Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages
Dwyer, D., Buciuman, M.-O., Ruef, A., Kambeitz, J. P., Dong, M. S., Stinson, C. L., Kambeitz‐Ilankovic, L., Degenhardt, F., Sanfelici, R., Antonucci, L. A., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.1163 · Cited by 39
Ghosh, H. S., Patel, R. V., Woodward, E. L., Greenwald, N. F., Bhave, V. M., Maury, E. A., Cello, G., Hoffman, S. E., Li, Y. Y., Gupta, H. V., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae164 · Cited by 37
Pessina, F., Navarria, P., Cozzi, L., Ascolese, A. M., Simonelli, M., Santoro, A., Tomatis, S., Riva, M., Fava, E., Scorsetti, M., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5222-3 · Cited by 37
Genomic and transcriptomic characterization of skull base chordoma
Sa, J. K., Lee, I., Hong, S. D., Kong, D., & Nam, D. (2016) · Oncotarget · doi:10.18632/oncotarget.13616 · Cited by 37
IGFBP2 expression predicts IDH-mutant glioma patient survival
Huang, L. E., Cohen, A. L., Colman, H., Jensen, R. L., Fults, D. W., & Couldwell, W. T. (2016) · Oncotarget · doi:10.18632/oncotarget.13329 · Cited by 37
Targeting Neoantigens in Glioblastoma
Johanns, T. M., Bowman-Kirigin, J. A., Liu, C. J., & Dunn, G. P. (2017) · Neurosurgery · doi:10.1093/neuros/nyx321 · Cited by 37
Age and surgical outcome of low-grade glioma in Sweden
Corell, A., Carstam, L., Smits, A., Henriksson, R., & Jakola, A. S. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.12973 · Cited by 40
Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
Trong, P. D., Roesch, S., Mairbäurl, H., Pusch, S., Unterberg, A. W., Herold‐Mende, C. C., & Warta, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102903 · Cited by 37
New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
Mhaidly, R., Krug, A., Gaulard, P., Lemonnier, F., Ricci, J., & Verhoeyen, E. (2020) · Oncogenesis · doi:10.1038/s41389-020-00259-x · Cited by 39
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- Emory University (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2481-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4530011
- OpenAlex
- W1812256879
- Cited by
- 3,148
- References
- 54
- Citations by year
- 2026: 139 · 2025: 196 · 2024: 248 · 2023: 282 · 2022: 371 · 2021: 341 · 2020: 366 · 2019: 314 · 2018: 311 · 2017: 284 · 2016: 226 · 2015: 60
- FWCI
- 164.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, U54HG007990)
- National Cancer Institute (U24CA194362, U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, U24CA143858, U24CA126543, U24CA144025, U24CA126563, U01CA168394, U24CA143866, U24CA143883, U24CA143845, U24CA126544, R01CA163722, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA008748, P30CA016672, U24CA143731)
- National Institute of Neurological Disorders and Stroke (R01NS081125)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioma molecular subtypes, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, NOTCH1 mutation, CIC mutation, glioblastoma, prognostic factors, DNA methylation, DNA copy number, gene expression, microRNA expression
- MeSH terms
- Adolescent, Adult, Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA, Neoplasm, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Mutation, Signal Transduction, Cluster Analysis, Proportional Hazards Models, Genes, p53, Sequence Analysis, DNA, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
